In this study, we investigated whether RANK expression, as part of the denosumab target pathway, a) may retrospectively identify a subgroup of patients with additional clinical benefit of denosumab or b) may predict response to nab-paclitaxel NACT....However, the pCR rate was higher in the RANKhigh subgroup compared to RANKlow (50% vs. 39%, OR: 1.52; 95%CI 1.04-2.21; p=0.037). RANK expression constituted an independent predictor of response to NACT frequently in patients with luminal-like subtype (HR+/HER2-; OR: 2.98; 95%CI 1.30-6.79; p=0.010)....We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.